<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We recently demonstrated that blockade of the platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> receptor <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP) Ibalpha protects mice from <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (VWF) is the major ligand for GPIbalpha, GPIbalpha can engage other counterreceptors on endothelial cells, platelets, and leukocytes (eg, Mac-1 or P-selectin) potentially involved in <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
<SENT sid="2" pm="."><plain>To further analyze whether VWF is of particular relevance for <z:hpo ids='HP_0001297'>stroke</z:hpo> development, VWF(-/-) mice underwent 60 minutes of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>After 24 hours, VWF(-/-) mice had significantly smaller infarctions (P&lt; .05) and less severe neurologic deficits (P&lt; .01) compared with controls </plain></SENT>
<SENT sid="4" pm="."><plain>This effect was sustained after 1 week, and <z:mp ids='MP_0001915'>intracranial bleeding</z:mp> was absent in VWF(-/-) mice as revealed by serial magnetic resonance imaging </plain></SENT>
<SENT sid="5" pm="."><plain>Hydrodynamic injection of a VWF-encoding plasmid restored the susceptibility for <z:hpo ids='HP_0001297'>stroke</z:hpo> in VWF(-/-) mice </plain></SENT>
<SENT sid="6" pm="."><plain>This study indicates that VWF is critically involved in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Hence, targeted inhibition of the GPIbalpha-VWF pathway might become a promising therapeutic option </plain></SENT>
</text></document>